BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Private Ocean, LLC | 536 | $36,486 | 0.01% |
| Bridgewater Associates | 12,318 | $838,486 | 0.01% |
| CITIGROUP INC | 96,761 | $6,586,521 | 0.01% |
| Horizon Investments, LLC | 2,400 | $163,152 | 0.01% |
| Citadel Advisors | 312,533 | $21,274,121 | 0.01% |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | 4,721 | $321,358 | 0.01% |
| CLEAR STREET MARKETS LLC | 733 | $50 | 0.01% |
| MML INVESTORS SERVICES, LLC | 12,570 | $856 | 0.01% |
| JPMORGAN CHASE & CO | 601,207 | $40,924,158 | 0.01% |
| OSAIC HOLDINGS, INC. | 47,325 | $3,222,104 | 0.01% |
| QUADRANT CAPITAL GROUP LLC | 797 | $54,252 | 0.01% |
| PRUDENTIAL PLC | 6,693 | $455,593 | 0.01% |
| SYNOVUS FINANCIAL CORP | 6,766 | $460,562 | 0.01% |
| Cetera Advisor Networks LLC | 12,506 | $851,249 | 0.01% |
| Global Retirement Partners, LLC | 1,514 | $101,135 | 0.01% |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 23,621 | $1,607,861 | 0.01% |
| MILLENNIUM MANAGEMENT LLC | 138,136 | $9,402,918 | 0.01% |
| BANK OF MONTREAL /CAN/ | 190,429 | $15,390,471 | 0.01% |
| ALLIANCEBERNSTEIN L.P. | 174,087 | $11,850,102 | 0.01% |
| SG Americas Securities, LLC | 5,862 | $399 | 0.01% |
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BIO-TECHNE CORP's shareholders in Q3 2023. To view BIO-TECHNE CORP's shareholder history, click here.